Isogenica is presenting at the 6th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference

Oct 7, 2021

Isogenica is excited to announce its attendance at the MarketsandMarkets Biomarker and Companion Diagnostics Conference, October 12-14 2021

Isogenica’s Associate Director of Discovery, Marion Cubitt, will be presenting at the 6th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference. 

Marion will be presenting the latest Isogenica VHH data on VHH single domain antibodies as a diagnostic tool for in vivo and ex vivo biomarker assessment.

INVITED SPEAKER PRESENTATION

(17:30 BST, 14th Sept)

Do not miss out on this unique opportunity to learn about the exciting new data from Isogenica’s collaboration with the University of Hull’s Positron Emission Tomography Research Centre (PETRC) on VHH as Antibody Radio Conjugates.

The presentation will cover:

  • Introduction to VHH antibody fragments and their unique properties.
  • VHH radio-conjugates for in vivo tumour profiling
  • Robustness of VHHs tools for ex vivo diagnostic applications

VHH are physically robust and can be conjugated to radio-isotopes, whilst maintaining selective targeting of tumour epitopes, enabling versatile application in theranostics.

Due to their small size, VHH are rapidly cleared from the blood through the kidneys. This has an added advantage in a radio imaging context as it limits the prolonged patient exposure to radioactive isotopes.

Furthermore, VHH’s small size and in vivo stability, enables better penetration of hostile environments, such as the ones in solid tumours. This leads to radio imaging with better resolution and speed.

If Isogenica VHH antibodies have application in your discovery projects or you would like to learn more about partnering with Isogenica, get in touch and we will be glad to schedule a meeting.

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”

Contact

Mandeep Sehmi,
Business Development

T +44 1799 533 680

E mandeep.sehmi@isogenica.com

Contact us